Skip to content

Clinical trials

Phase 2 Bile Duct Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Bile Duct Neoplasms Phase: Phase 2 Clear all

70 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20013
20024
20032
20043
20052
20063
20074
20081
20092
20104
20111
20132
20145
20151
20161
20174
20182
20193
20204
20222
20232
20243
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed34
Terminated15
Unknown status8
Recruiting5
Active, not recruiting4
Not yet recruiting2
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)18
Alliance for Clinical Trials in Oncology2
Memorial Sloan Kettering Cancer Center2
SWOG Cancer Research Network2
Seoul National University Hospital2
AIO-Studien-gGmbH1
ASLAN Pharmaceuticals1
Academic and Community Cancer Research United1
Basilea Pharmaceutica1
Beijing Biostar Pharmaceuticals Co., Ltd.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Bile Duct Neoplasms70
Gallbladder Neoplasms40
Cholangiocarcinoma26
Carcinoma, Hepatocellular22
Liver Neoplasms15
Biliary Tract Neoplasms11
Pancreatic Neoplasms10
Colorectal Neoplasms7
Stomach Neoplasms6
Colonic Neoplasms4

Trials

Showing 76 to 70 of 70. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.